Through rigorous sensitivity analyses, we ultimately identified three proteins as priority candidates with significant druggable potential: CDH15 for ILD excluding IPF, ADAM15 for both IPF and ILD, and LTBR for sarcoidosis. Here, CDH15 is linked to interstitial lung disease.